Fakilahyel Mshelbwala, DO
Interventional Cardiology · Phoenix, AZNPI 1124558515
Payments from drug & device makers
Across 39 payments — averaging $101.88 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$2K
- Boston Scientific$530
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$418
- Philips North America LLC$196
- Edwards Lifesciences$175
- Chiesi USA, Inc.$150
- plus $402 from 6 others
Across 1 payment — averaging $18.70 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Abiomed$19
What the payments were for
- Speaking & faculty fees$90023%
- Travel & lodging$49412%
- Food & beverage$2,58065%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 14 | $2,102 |
| Boston Scientific | 5 | $530 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $418 |
| Philips North America LLC | 3 | $196 |
| Edwards Lifesciences | 3 | $175 |
| Chiesi USA, Inc. | 5 | $150 |
| AstraZeneca | 1 | $128 |
| Novo Nordisk | 1 | $119 |
| Inspire Medical Systems, Inc. | 1 | $97 |
| Boehringer Ingelheim | 1 | $22 |
| Terumo Medical Corporation | 1 | $22 |
| Amgen | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$1,704
- LifeVest$331
- GENERAL ATHERECTOMY$154
- General - Balloon Catheters$143
- SAPIEN 3 Ultra RESILIA$133
- Ranger$131
- Ozempic$119
How this compares
$3,973 in reported general payments places this provider in the 20th percentile of 223 interventional cardiology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ClopidogrelClopidogrel Bisulfate | 33 | $705 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Phoenix
- Paul SorajjaPhoenix$8.8M
- Timothy ByrnePhoenix$2.1M
- Mohamad LazkaniPhoenix$1.1M
- Parminder SinghPhoenix$854K
- Akil LoliPhoenix$506K
- Haidar YassinPhoenix$457K
- Michael WhitePhoenix$417K
- Nezar FallujiPhoenix$348K
- Floyd FortuinPhoenix$263K
- Nishant GuptaPhoenix$196K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.